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ABSTRACT
Aims To develop a ﬂuorescence in-situ hybridisation
(FISH) assay for detecting p16/CDKN2A deletion on
parafﬁn tissue sections for use as an ancillary test to
distinguish reactive from malignant mesothelial
proliferations.
Method Dual-colour FISH for p16/CDKN2A and
chromosome 9 (CEP-9) was performed on 11 benign
mesothelial proliferations and 54 malignant pleural
mesothelioma (MPM) cases to establish cut-off values
for p16/CDKN2A deletion. A third MYC probe was used
to verify cases showing homozygous deletion. Eight
equivocal biopsies were used for assay testing.
Results Cut-off values for p16/CDKN2A deletion were
calculated based on FISH signalling patterns obtained
from the benign controls (mean percent nuclei plus three
standard deviations). Hemizygous deletion was deﬁned
as >44% of nuclei showing the hemizygous (one p16/
CDKN2A, two CEP-9 signals) or >15% of nuclei showing
the monosomy (one p16/CDKN2A, one CEP-9 signal)
deletion patterns. None of the benign cases showed
a homozygous deletion pattern (no p16/CDKN2A,a t
least one CEP-9 signal). In the malignant cases, the
percentage of nuclei showing homozygous deletion
ranged from 1% to 87%. Therefore, the cut-off value for
homozygous deletion was deﬁned as >10%. P16/
CDKN2A deletion was detected in 61% (33/54) of MPM
cases. Among the equivocal biopsies, four showed
homozygous and one showed hemizygous p16/CDKN2A
deletion. Age over 60 years, asbestos exposure and p16/
CDKN2A deletion were associated with a worse
prognosis.
Conclusion Distinction between benign and malignant
mesothelial proliferations can be diagnostically
challenging. FISH for p16/CDKN2A deletion is a useful
test for conﬁrming the diagnosis of MPM.
INTRODUCTION
Differentiating benign pleural mesothelial prolifer-
ationsfrommalignantpleuralmesothelioma(MPM)
on routine biopsies with limited tissue can pose
a diagnostic challenge.
1 If the biopsy fails to capture
invasion into fat or skeletal muscle, mesothelioma
can be difﬁcult to differentiate from reactive meso-
thelial hyperplasia.
1 Many epithelioid MPM have
monotonous-appearing cells that are deceptively
bland. Similarly, the desmoplastic variant of meso-
thelioma is difﬁcult to distinguish from ﬁbrous
pleuritis in the absence of frankly sarcomatous foci
or invasion into adjacent structures.
1 Conversely,
reactive mesothelial proliferations can exhibit
cytological and architectural features that mimic
malignancy. Given the prognostic and treatment
implications, accurate distinction between benign
and malignant mesothelial proliferations is
imperative.
Immunohistochemical markers can readily iden-
tify cells of mesothelial origin, but to date, no
markers reliably distinguish benign from malignant
mesothelial proliferations.
1 2 The use of epithelial
membrane antigen,
3 p53,
45desmin,
6 P-glycopro-
tein,
7 platelet-derived growth factor receptor
b-chain,
8 b-catenin
9e11 and GLUT-1
12 have been
reported as markers of malignancy; nevertheless, all
lack sufﬁcient sensitivity and speciﬁcity for clinical
adoption and implementation.
161 31 4
Deletion involving the 9p21 locus, the site of the
cyclin-dependent kinase inhibitor 2A/p16 gene
(p16/CDKN2A), frequently occurs in mesothe-
lioma.
15 Homozygous deletion has been reported in
22e74% of mesotheliomas.
16e21 However, previous
studies lacked details on assay development. In
ﬂuorescence in situ hybridisation (FISH) it has been
shown that for each probe a cut-off value needs to
be determined based on normal nuclei of speciﬁc
target nuclei and from different subjects.
22 A crit-
ical factor affecting the accurate interpretation of
FISH signals, particularly when looking for dele-
tions, is the establishment of cut-off values for all
signal patterns that might appear with a given
assay.
23 The objectives of this study were to:
(a) develop a FISH assay for clinical use in the
diagnosis of MPM, by establishing cut-off values
for the detection of p16/CDKN2A deletion on
formalin-ﬁxed parafﬁn-embedded (FFPE) material;
and (b) test the assay on tissue sections from
equivocal cases with known clinical outcome.
MATERIALS AND METHODS
Samples for assay development
Withinstitutionalresearchethicsboardapproval,we
collected 54 archival biopsy and resection specimens
with clinically, radiologically and histopathologi-
callyconﬁrmeddiagnosisofMPM(42epithelioid,11
biphasic and 1 sarcomatoid variant) and 11 cases of
reactive mesothelial proliferations as negative
controls,toestablishthecut-offvalues.Clinicaldata
collectedincludedage,sex,smokinghistory,previous
asbestos exposure and clinical outcome.
Samples for assay testing
We collected prospectively eight biopsy samples in
which the distinction between a benign mesothelial
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Original articleproliferation from MPM could not be made deﬁnitively by
histology and immunohistochemistry alone, but were proven
malignant clinically or by repeat biopsy. The samples were
typically small biopsies lacking evidence of true stromal inva-
sion, such as invasion into fat or muscle, thereby making it
difﬁcult to distinguish from reactive mesothelial cell entrap-
ment. Immunohistochemistry conﬁrmed their mesothelial cell
origin by positive staining for calretinin or CK5/6 and negative
staining for markers of metastatic adenocarcinoma (eg, BerEp4,
CEA, TTF-1).
Fluorescence in situ hybridisation
Dual-colour FISH was performed using a commercially available
Spectrum Orange-labelled locus speciﬁc p16(9p21) probe and
Spectrum Green-labelled chromosome 9 centromeric probe
(Vysis LSI p16 (9p21) SpectrumOrange/CEP9 SpectrumGreen
Probe; Abbott Laboratories, Des Plaines, Illinois, USA). Slides
(4 mm sections) were deparafﬁnised in xylene, followed by
rehydration and pretreatment in 10 mM sodium citrate (pH 6.0)
at 808C for 45 min. After washing in 23 standard saline citrate
for 5 min, sections were digested with pepsin (37500 U in 0.1 N
HCl) (Sigma, St Louis, Missouri, USA) at 378C for 10e25 min.
Slides were co-denatured with the probes, allowed to hybridise
and washed according to the manufacturer’s protocol.
With tissue sections potential loss of target sequences by
nuclear truncation can be problematic for analysis of deletions.
To verify that samples showing a deletion pattern are not due to
nuclear truncation or differences in hybridisation efﬁciency
between the p16/CDKN2A and CEP-9 probes, FISH was repeated
in homozygous deleted cases with a third in-house MYC probe
(BAC RP11-367L7), which is known to be not deleted in
mesothelioma. The MYC probe was labelled with DEAC-dUTP
(PerkinElmer, Waltham, Massachusetts, USA) using the Vysis
nick translation kit (Abbott Laboratories) according to the
manufacturer’s protocol. Slides were analysed, blinded from the
clinical data, using a Zeiss microscope (Axioplan 2, Jena,
Germany) equipped with the appropriate ﬁlters. A minimum of
100 non-overlapped intact (uniform DAPI staining with intact
nuclear contours) interphase nuclei of consecutive cells in at
least two different areas of the section were scored. An H&E
stained section was used to verify the presence of tumour.
Statistics
Survival was deﬁned as time between date of surgery and date of
death or last follow-up. Each biomarker was tested for associa-
tion with survival using the Cox proportional hazards model.
The percent survival at every point in time was estimated using
the KaplaneMeier method. Associations between p16/CDKN2A
status and the clinical parameters were performed using the
Wilcoxon rank-sum test.
RESULTS
Cut-off values for normal p16/CDKN2A FISH signalling
FISH was performed on 11 cases of reactive mesothelial prolif-
erations. Cut-off levels were calculated as the mean percentage
+ three standard deviations (SD) of nuclei showing one signal as
previously described.
22 None of the reactive cases showed the
p16/CDKN2A homozygous deletion pattern, which was deﬁned
as loss of both p16/CDKN2A signals with at least one CEP-9
signal or 0SpO/1-2SpG (table 1). Therefore, a cut-off for
homozygous deletion could not be established using the benign
controls. The hemizygous loss pattern (one p16/CDKN2A signal
with two CEP-9 signals or 1SpO/2SpG) was noted in 1e10%
(mean 6.3%) of nuclei. The monosomy pattern (one p16/
CDKN2A signal with one CEP-9 signal or 1SpO/1SpG) was
present in 6e34% (mean 19.9%) of nuclei. As monosomy
pattern could be interpreted as hemizygous deletion, hemi-
zygous p16/CDKN2A deletion was deﬁned as >44% of nuclei
showing 1SpO/1SpG or >15% of nuclei showing 1SpO/2SpG
(table 2).
Malignant pleural mesothelioma
Among MPM cases, the mean percentage of nuclei with
homozygous deletion pattern was 61% (range 1e87%), with
only three cases showing a percentage less than 30%. These
three cases also showed hemizygous deletion as deﬁned by the
established cut-offs. To mitigate uncertainty from artifactual
loss of signals due to nuclear sectioning, a cut-off of >10% for
0SpO/1-2SpG was deﬁned for homozygous deletion (table 2).
Using this cut-off, homozygous p16/CDKN2A deletion was
detected in 23/54 (43%) of MPM cases (table 3, ﬁgure 1).
Homozygous loss was conﬁrmed by repeating the FISH with the
addition of the MYC probe. Eleven of the 23 homozygous cases
showed concurrent hemizygous (1SpO/2SpG) deletion.
Hemizygous-only deletion was seen in 10/54 (18%) cases,
three (5%) of which had the 1SpO/1SpG deletion pattern and
seven (13%) had the 1SpO/2SpG deletion pattern. Two cases
showed p16/CDKN2A ampliﬁcation, deﬁned as at least 10% of
nuclei with a SpO:SpG ratio of 2 or higher, in 32% and 20% of
nuclei, respectively (ﬁgure 1D). PCR-direct sequencing of the
p16/CDKN2A gene on both cases did not identify mutations
(data not shown). P16/CDKN2A deletion shows 61% sensitivity
and 100% speciﬁcity for MPM.
Testing samples
Among the eight equivocal biopsies, seven had sufﬁcient tissue
for evaluation. Four cases showed homozygous p16/CDKN2A
deletion (mean 49%, range 16e75%) and one showed hemi-
zygous (1SpO/2SpG) deletion. The pauci-cellular and cytologi-
cally bland nature of the two desmoplastic mesothelioma cases
Table 1 Copy number for p16/CDKN2A gene in benign mesothelial
cells
FISH signalling in benign
mesothelial cells Mean (%)*±SD Range (%)
2SpO/2SpG 63684 4 e75
0SpO/2SpG 0 0
0SpO/1SpG 0 0
1SpO/2SpG 6631 e10
1SpO/1SpG 20686 e34
*Percentage of nuclei showing the FISH signal pattern.
FISH, ﬂuorescence in situ hybridisation.
Table 2 Deﬁnitions for homozygous and hemizygous p16/CDKN2A
deletion determined by ﬂuorescence in situ hybridisation (FISH)
p16/CDKN2A
deletion pattern
FISH signal pattern Cut-off value for
% nuclei with FISH
signal pattern p16/CDKN2A (SpO) CEP-9 (SpG)
Homozygous No p16/CDKN2A
signal
0SpO
At least one CEP-9
signal
1-2SpG
>10%
Hemizygous One p16/CDKN2A
signal
1SpO
Two CEP-9 signals
2SpG
>15%
Hemizygous
(monosomy)
One p16/CDKN2A
signal
1SpO
One CEP-9 signal
1SpG
>44%
SpO, Spectrum Orange; SpG, Spectrum Green.
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normal from neoplastic spindle cells. All eight equivocal cases
were subsequently conﬁrmed to be MPM; seven patients died of
their disease and one showed advanced disease on imaging.
Prognostic signiﬁcance of p16/CDKN2A deletion
The mean age of patients at the time of surgery was 58 years and
17% were female. Asbestos exposure and a smoking history were
documented in 50% and 46% of patients, respectively. Correla-
tion of patient characteristics and p16/CDKN2A FISH status
with clinical outcome showed that age $60 (35% vs 20% survival
at 2 years; p¼0.026), asbestos exposure (39% vs 17% survival at
2 years; p¼0.039) and p16/CDKN2A deletion by FISH (50% vs
17% survival at 2 years; p¼0.039) were signiﬁcantly associated
with reduced survival on univariate analysis (ﬁgure 2). There was
no association between p16/CDKN2A deletion status and any of
the clinical parameters.
DISCUSSION
We demonstrate that FISH for p16/CDKN2A deletion can be
a clinically useful marker to conﬁrm a diagnosis of malignancy,
particularly in biopsies with limited material that lack deﬁnitive
evidence of invasion. Moreover, we determined cut-off values for
homozygous and hemizygous p16/CDKN2A deletion by FISH
on routine FFPE tissue sections and tested our assay using
equivocal cases. To conﬁrm the accuracy of the assay, a third
MYC probe was used to verify samples showing a homozygous
deletion pattern, thereby avoiding potential false positive
results. Using the established criteria, we show that hemizygous
deletion alone may occur in mesothelioma and is, in and of itself,
sufﬁcient for the diagnosis of malignancy.
The establishment of cut-off values for detecting deletions in
FFPE material requires special consideration because sectioning
creates truncation artifacts; therefore cut-offs need to be higher
than in samples containing intact nuclei,
23 and criteria for
deletion must account for this artifactual loss of signals. We
showed in our study that in reactive mesothelial cells, mono-
somy was identiﬁed in up to 34% of nuclei. Our overall rate of
p16/CDKN2A deletion in MPM was 61%; 43% homozygous and
18% hemizygous. Half of the homozygous deletion samples
included a concurrent hemizygous pattern suggesting genetic
tumour progression. Importantly, all MPM cases with low per
cent nuclei showing homozygous deletion pattern also showed
hemizygous deletion as deﬁned by our cut-offs. In cases with
hemizygous-onlydeletion,thesecondallelemaybeinactivatedby
other mechanisms such as promoter methylation and/or point
mutations. Alternatively, haploid deﬁciency by hemizygous
Table 3 Fluorescence in situ hybridisation for p16/CDKN2A gene copy
number in malignant mesothelioma
Homozygous
deletion*
Hemizygous
deletionz Ampliﬁcationy
Normal
diploid Total
Epithelioid 19 5 2 16 42
Sarcomatoid 0001 1
Biphasic 4502 1 1
Total 23 (43%) 10 (18%) 2 (4%) 19 (35%) 54
*>10% of tumour cells show 0SpO/2SpG.
yAt least 10% of tumour cell nuclei show SpO/SpG ratio $2.
z>15% of tumour cells show 1SpO/2SpG or >44% show 1SpO/1SpG.
Figure 1 Fluorescence in situ
hybridisation showing: (A) normal
p16/CDKN2A signalling in a benign
reactive mesothelial case;
(B) hemizygous (loss of one red signal);
and (C) homozygous (loss of both red
signals) loss of p16/CDKN2A in two
mesothelioma cases, respectively.
Inset: presence of MYC (blue signals)
probe in the absence of p16 signalling
conﬁrms the homozygous loss of p16.
(D) Ampliﬁcation of p16/CDKN2A in
a mesothelioma case.
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Original articledeletion in combination with other oncogenic events could be
sufﬁcient for malignant transformation.
Although 9p21 locus deletion by FISH on cytological prepa-
rations and tissue sections has been suggested as a clinical assay
for diagnosing MPM,
17 24 25 none of the previous reports have
provided details on the establishment of cut-offs to score the
FISH results on FFPE sections. Using FISH on 32 cytological
specimens (whole cell nuclei), Illei et al identiﬁed homozygous
p16/CDKN2A deletion in 85.7% (6/7) of cases with malignant
cytology and 100% (6/6) with suspicious cytology; no deletion
was detected in 19 cytologically negative specimens.
25 They
subsequently reported FISH on freshly imprinted tumour cells of
95 MPM and showed homozygous p16/CDKN2A deletion in
74% of cases and hemizygous loss in ﬁve cases (5%).
19 Their
cut-off for homozygous deletion was deﬁned as >20% of nuclei
with loss of both p16/CDKN2A signals with at least one CEP-9
signal. More recently, a study that combined FFPE whole
sections and tissue microarray (TMA) cores identiﬁed homozy-
gous p16/CDKN2A deletion in 67% (35/52) of MPM and 25%
(5/20) of peritoneal mesotheliomas.
17 A follow-up multi-insti-
tutional TMA study on epithelioid MPM detected homozygous
deletion in 60% (21/35) and hemizygous deletion in 8.6% (3/35)
of cases, but the criteria for hemizygosity was not clearly
deﬁned. In these latter two studies, homozygous p16/CDKN2A
deletion was deﬁned by the same cut-off used by Illei et al, but
without the rationale to justify the use of this cut-off in tissue
sections. Cut-off values for monosomy and trisomy depend on
the type of probe and target nuclei; the lack of proper controls
can result in misdiagnosis of chromosomal abnormalities.
22
Inadequate control samples may inﬂuence cut-off values and
consequently the sensitivity of the FISH assay.
22
P16/CDKN2A deletion was associated with a worse outcome,
with a 50% two-year survival for lack of p16/CDKN2A deletion
versus 17% survival for patients with the deletion. This is
consistent withprevious studies identifying loss of p16/CDKN2A
as a poor prognostic indicator.
24 26 27 Outcome analyses showed
that age over 60 years and previous asbestos exposure were
associated with a signiﬁcantly worse survival.
In conclusion, FISH for p16/CDKN2A deletion on FFPE
sections is a clinically relevant conﬁrmatory test for diagnosing
MPM. In equivocal cases, the identiﬁcation of deletion using the
established cut-offs (table 2) may prevent delay in diagnosis and
allow earlier management for this fatal disease. The test also
provides important prognostic information and can be imple-
mented in clinical laboratories with routine FISH service.
Funding This project was supported by grants from the Physicians’ Services
Incorporated Foundation (PSI) and the Canadian Cancer Society/National Cancer
Institute of Canada. The funding sources had no involvement in the study design,
collection, analysis and interpretation of data or in the writing of the report or decision
to submit the paper for publication.
Competing interests None.
Ethics approval This study was conducted with the approval of the University Health
Network.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant
mesothelial proliferations. Am J Surg Pathol 2000;24:1183e200.
2. King J, Thatcher N, Pickering C, et al. Sensitivity and speciﬁcity of
immunohistochemical antibodies used to distinguish between benign and malignant
pleural disease: a systematic review of published reports. Histopathology
2006;49:561e8.
3. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane
antigen and silver-stained nucleolar organizer regions testing in the differential
diagnosis of mesothelioma from benign reactive mesothelioses. Cancer
1998;82:583e90.
4. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of
reactive processes from malignancy in pleural biopsy specimens. Hum Pathol
1994;25:443e8.
5. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between
benign and malignant mesothelial proliferations using formalin-ﬁxed parafﬁn sections.
J Pathol 1992;168:377e81.
6. Attanoos RL, Grifﬁn A, Gibbs AR. The use of immunohistochemistry in distinguishing
reactive from neoplastic mesothelium. A novel use for desmin and comparative
evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-
receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231e8.
7. Ramael M, van den Bossche J, Buysse C, et al. Immunoreactivity for P-170
glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of
the pleura using the murine monoclonal antibody JSB-1. J Pathol 1992;
167:5e8.
8. Ramael M, Buysse C, van den Bossche J, et al. Immunoreactivity for the beta
chain of the platelet-derived growth factor receptor in malignant mesothelioma
and non-neoplastic mesothelium. J Pathol 1992;167:1e4.
9. Abutaily AS, Collins JE, Roche WR. Cadherins, catenins and APC in pleural
malignant mesothelioma. J Pathol 2003;201:355e62.
Figure 2 The KaplaneMeier curve for survival in malignant mesothe-
liomas with p16/CDKN2A deletion versus no p16/CDKN2A deletion by
ﬂuorescence in situ hybridisation.
Take-home messages
< Establishing cut-off values for p16/CDKN2A deletion using
appropriate controls is essential to ﬂuorescence in situ
hybridisation (FISH) assay development on parafﬁn sections.
< Detection of hemizygous p16/CDKN2A deletion alone is
supportive of the diagnosis of malignant pleural mesothe-
lioma.
< Presence of p16/CDKN2A deletion by FISH is associated with
a worse prognosis in malignant pleural mesothelioma (MPM).
< The following p16/CDKN2A deletion patterns were deﬁned by
our FISH assay:
– Homozygous deletion: no p16/CDKN2A (0SpO) and at
least one CEP-9 signal (1-2SpG) in >10% of scored nuclei.
– Hemizygous deletion: one p16/CDKN2A signal (1SpO) and
two CEP-9 (2SpG) in >15% of nuclei.
– Hemizygous deletion: one p16/CDKN2A signal (1SpO) and
one CEP-9 (1SpG) in >44% of nuclei.
J Clin Pathol 2010;63:630e634. doi:10.1136/jcp.2010.076794 633
Original article10. Dai Y, Bedrossian CW, Michael CW. The expression pattern of beta-catenin in
mesothelial proliferative lesions and its diagnostic utilities. Diagn Cytopathol
2005;33:320e4.
11. Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma:
evidence of dishevelled overexpression and transcriptional activity of beta-catenin.
Cancer Res 2003;63:4547e51.
12. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can
discriminate between reactive mesothelium and malignant mesothelioma. Mod
Pathol 2007;20:215e20.
13. Cury PM, Butcher DN, Corrin B, et al. The use of histological and
immunohistochemical markers to distinguish pleural malignant mesothelioma and in
situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural ﬁbrosis.
J Pathol 1999;189:251e7.
14. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has
a limited role in the diagnosis of malignant mesothelioma. A study of thirteen
antibodies. Am J Clin Pathol 2001;116:253e62.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially
involved in genesis of many tumour types. Science 1994;264:436e40.
16. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of
9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547e51.
17. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21
homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;
21:742e7.
18. Hirao T, Bueno R, Chen CJ, et al. Alterations of the p16(INK4) locus in human
malignant mesothelial tumors. Carcinogenesis 2002;23:1127e30.
19. Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and
codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural
mesotheliomas. Clin Cancer Res 2003;9:2108e13.
20. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependent-
kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma.
Int J Cancer 1998;75:649e53.
21. Xio S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant
mesothelioma. Oncogene 1995;11:511e15.
22. Tibiletti MG. Speciﬁcity of interphase ﬂuorescence in situ hybridisation for detection
of chromosome aberrations in tumour pathology. Cancer Genet Cytogenet
2004;155:143e8.
23. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of
lymphoma-associated chromosomal abnormalities in routine parafﬁn-embedded
tissue. J Mol Diagn 2006;8:141e51.
24. Dacic S, Kothmaier H, Land S, et al. Prognostic signiﬁcance of p16/cdkn2a loss in
pleural malignant mesotheliomas. Virchows Arch 2008;453:627e35.
25. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic
marker for malignant mesothelioma in body cavity effusions. Cancer 2003;99:51e6.
26. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor
survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res
2005;11:3303e8.
27. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression proﬁling of pleural
mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as
prognostic factors and critical evaluation of microarray-based prognostic prediction.
Cancer Res 2006;66:2970e9.
634 J Clin Pathol 2010;63:630e634. doi:10.1136/jcp.2010.076794
Original article